FindTrial
Sign In

To study the usefulness of von willibrand factor to ADAMTS-13 ratio as a predictor of development of extrahepatic organ failure in acute on chronic liver failure patients.

To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients. - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/058349
Enrollment
50
Registered
2023-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: NIL: NIL

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the patients with age >18 years who are diagnosed having ACLF fulfilling APASL ACLF criteria and do not have any extrahepatic organ failure at enrollment.

Exclusion criteria

Exclusion criteria: 1) Patients on antiplatelet or anticoagulant therapy for at any point of time in last 7 days 2) Pregnant female 3) Patient receiving N-acetyl cysteine (NAC) (interferes with the vWF assay)

Design outcomes

Primary

MeasureTime frame
Proportion of patients developing of any organ failures by day 7 with increased vWF: ADAMTS 13 ratioTimepoint: Day 7—

Secondary

MeasureTime frame
Proportion of patients having change in vWF, ADAMTS 13 level and vWF Ag : ADAMTS-13 ratio at day 7 different therapies (Nutrition, Plasma exchange, Prednisolone, Nucleos(t)ide analogue in hepatitis B) on vWF, ADAMTS 13 level and vWF Ag : ADAMTS-13 ratio.Timepoint: Day 28;Proportion of patients having change in vWF, ADAMTS 13 level and vWF Ag : ADAMTS-13 ratio compared to change in AARC, MELD, CLIF-ACLF scoresTimepoint: Day 28;Proportion of patients with increased vWF, ADAMTS 13 level and vWF Ag : ADAMTS-13 ratio across different grades of AARC ACLFTimepoint: Day 28;Proportion of patients alive by day 28 without transplant with increased day 1 and day 4 vWF and ADAMTS 13 levelTimepoint: Day 28;Proportion of patients alive by day 28 without transplant with increased vWF: ADAMTS 13 ratioTimepoint: Day 28;Proportion of patients developing of any organ failures by day 7 with increased day 1 and day 4 vWF and ADAMTS 13 levelTimepoint: Day 7—

Countries

India

Contacts

Public ContactDr Manoj Kumar Sharma

Institute of Liver and Biliary Sciences

manojkumardm@gmail.com01146300000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026